Ticarcillin clavulanate indications and usage
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mohamed Moubarak, M.D. [2]
Indications and Usage
TIMENTIN® is indicated in the treatment of infections caused by susceptible isolates of the designated bacteria in the conditions listed below: 1.1 Septicemia
Septicemia (including bacteremia) caused by β‑lactamase–producing isolates of Klebsiella spp.*, Escherichia coli*, Staphylococcus aureus*, or Pseudomonas aeruginosa* (or other Pseudomonas species*)
- Lower Respiratory Infections
Lower respiratory infections caused by β‑lactamase–producing isolates of S. aureus, Haemophilus influenzae*, or Klebsiella spp.*
- Bone and Joint Infections
Bone and joint infections caused by β‑lactamase–producing isolates of S. aureus
- Skin and Skin Structure Infections
Skin and skin structure infections caused by β‑lactamase–producing isolates of S. aureus, Klebsiella spp.*, or E. coli*
- Urinary Tract Infections
Urinary tract infections (complicated and uncomplicated) caused by β‑lactamase–producing isolates of E. coli, Klebsiella spp., P. aeruginosa* (or other Pseudomonas spp.*), Citrobacter spp.*, Enterobacter cloacae*, Serratia marcescens*, or S. aureus*
- Gynecologic Infections
Endometritis caused by β‑lactamase–producing isolates of Prevotella melaninogenicus*, Enterobacter spp. (including E. cloacae*), E. coli, Klebsiella pneumoniae*, S. aureus, or Staphylococcus epidermidis
- Intra-abdominal Infections
Peritonitis caused by β‑lactamase–producing isolates of E. coli, K. pneumoniae, or Bacteroides fragilis* group
- Efficacy for this organism in this organ system was studied in fewer than 10 infections.
To reduce the development of drug‑resistant bacteria and maintain the effectiveness of TIMENTIN and other antibacterial drugs, TIMENTIN should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.[1]
References
Adapted from the FDA Package Insert.